FDA committee to discuss adverse effects of testosterone products

July 17, 2014 6:39 PM

3 0

FDA committee to discuss adverse effects of testosterone products

The 3D printing revolution

(Reuters) - The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy.

Also read: EU regulator accepts Sanofi/Regeneron's Dupixent product for review

Read more

To category page

Loading...